|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eyre R, Feltbower RG, Mubwandarikwa E,
Eden TO and McNally RJ: Epidemiology of bone tumours in children
and young adults. Pediatr Blood Cancer. 53:941–952. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harrison DJ, Geller DS, Gill JD, Lewis VO
and Gorlick R: Current and future therapeutic approaches for
osteosarcoma. Expert Rev Anticancer Ther. 18:39–50. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baudino TA: Targeted cancer therapy: The
next generation of cancer treatment. Curr Drug Discov Technol.
12:3–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tao Y, Wang Y, Wang X, Wang C, Bao K, Ji
L, Jiang G and Hong M: Calycosin suppresses epithelial derived
initiative key factors and maintains epithelial barrier in allergic
inflammation via TLR4 mediated NF-κB pathway. Cell Physiol Biochem.
44:1106–1119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dong L, Yin L, Chen R, Zhang Y, Hua S,
Quan H and Fu X: Anti-inflammatory effect of Calycosin glycoside on
lipopolysaccharide-induced inflammatory responses in RAW 264.7
cells. Gene. 675:94–101. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Duan X, Meng Q, Wang C, Liu Z, Liu Q, Sun
H, Sun P, Yang X, Huo X, Peng J and Liu K: Calycosin attenuates
triglyceride accumulation and hepatic fibrosis in murine model of
non-alcoholic steatohepatitis via activating farnesoid X receptor.
Phytomedicine. 25:83–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Y, Che G, Di Z, Sun W, Tian J and Ren
M: Calycosin-7-O-β-D-glucoside attenuates myocardial
ischemia-reperfusion injury by activating JAK2/STAT3 signaling
pathway via the regulation of IL-10 secretion in mice. Mol Cell
Biochem. 463:175–187. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qiu R, Li X, Qin K, Chen X, Wang R, Dai Y,
Deng L and Ye Y: Antimetastatic effects of calycosin on
osteosarcoma and the underlying mechanism. Biofactors. 45:975–982.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu G, Niu M, Qin J, Wang Y and Tian J:
Inactivation of Rab27B-dependent signaling pathway by calycosin
inhibits migration and invasion of ER-negative breast cancer cells.
Gene. 709:48–55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El-Kott AF, Al-Kahtani MA and Shati AA:
Calycosin induces apoptosis in adenocarcinoma HT29 cells by
inducing cytotoxic autophagy mediated by SIRT1/AMPK-induced
inhibition of Akt/mTOR. Clin Exp Pharmacol Physiol. 46:944–954.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun H, Yin M, Qian W and Yin H: Calycosin,
a phytoestrogen isoflavone, induces apoptosis of estrogen
receptor-positive MG-63 osteosarcoma cells via the
phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of
rapamycin (mTOR) pathway. Med Sci Monit. 24:6178–6186. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ning L, Wan S, Jie Z, Xie Z, Li X, Pan X,
Wan X, Chen W, Huang H, Wang J, et al: Lycorine induces apoptosis
and G1 phase arrest through ROS/p38 MAPK signaling pathway in human
osteosarcoma cells in vitro and in vivo. Spine (Phila Pa 1976).
45:E126–E139. 2019. View Article : Google Scholar
|
|
15
|
Chen J, Hou R, Zhang X, Ye Y, Wang Y and
Tian J: Calycosin suppresses breast cancer cell growth via
ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.
PLoS One. 9:e912452014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang B, Wang D, Guo F and Xuan C:
Mitochondrial membrane potential and reactive oxygen species in
cancer stem cells. Fam Cancer. 14:19–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiu R, Ma G, Li X, Shi Q, Li X, Zhou X,
Tang Y, Xie Z, Liao S, Qin Y, et al: Clinical case report of
patients with osteosarcoma and anticancer benefit of calycosin
against human osteosarcoma cells. J Cell Biochem. 120:10697–10706.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fleischer A, Ghadiri A, Dessauge F,
Duhamel M, Rebollo MP, Alvarez-Franco F and Rebollo A: Modulating
apoptosis as a target for effective therapy. Mol Immunol.
43:1065–1079. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Creagh EM: Caspase crosstalk: Integration
of apoptotic and innate immune signalling pathways. Trends Immunol.
35:631–640. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou Y, Liu QH, Liu CL and Lin L:
Calycosin induces apoptosis in human ovarian cancer SKOV3 cells by
activating caspases and Bcl-2 family proteins. Tumour Biol.
36:5333–1339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Palmer CS, Osellame LD, Stojanovski D and
Ryan MT: The regulation of mitochondrial morphology: Intricate
mechanisms and dynamic machinery. Cell Signal. 23:1534–1545. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiong S, Mu T, Wang G and Jiang X:
Mitochondria-mediated apoptosis in mammals. Protein Cell.
5:737–749. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Siu WP, Pun PB, Latchoumycandane C and
Boelsterli UA: Bax-mediated mitochondrial outer membrane
permeabilization (MOMP), distinct from the mitochondrial
permeability transition, is a key mechanism in diclofenac-induced
hepatocyte injury: Multiple protective roles of cyclosporin A.
Toxicol Appl Pharmacol. 227:451–461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jergens A, Young J, Moore D, Wang C,
Hostetter J, Augustine L, Allenspach K, Schmitz S and Mosher C:
Bcl-2/Caspase 3 mucosal imbalance favors T cell resistance to
apoptosis in dogs with inflammatory bowel disease. Vet Immunol
Immunopathol. 158:167–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu T, Wang NS, Fu LL, Ye CY, Yu SQ and Mei
CL: Celecoxib inhibits growth of human autosomal dominant
polycystic kidney cyst-lining epithelial cells through the
VEGF/Raf/MAPK/ERK signaling pathway. Mol Biol Rep. 39:7743–7753.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cuenda A and Rousseau S: p38 MAP-kinases
pathway regulation, function and role in human diseases. Biochim
Biophys Acta. 1773:1358–1375. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin RC, Yang SF, Chiou HL, Hsieh SC, Wen
SH, Lu KH and Hsieh YH: Licochalcone a-induced apoptosis through
the activation of p38MAPK pathway mediated mitochondrial pathways
of apoptosis in human osteosarcoma cells in vitro and in vivo.
Cells. 8:14412019. View Article : Google Scholar
|
|
29
|
Li Z, Tang X, Luo Y, Chen B, Zhou C, Wu X,
Tang Z, Qi X, Cao G, Hao J, et al: NK007 helps in mitigating
paclitaxel resistance through p38MAPK activation and HK2
degradation in ovarian cancer. J Cell Physiol. Feb 20–2019.(Epub
ahead of print). doi: 10.1002/jcp.28278.
|
|
30
|
Zhang J, Li J, Song H, Xiong Y, Liu D and
Bai X: Hydroxysafflor yellow A suppresses angiogenesis of
hepatocellular carcinoma through inhibition of p38 MAPK
phosphorylation. Biomed Pharmacother. 109:806–814. 2019. View Article : Google Scholar : PubMed/NCBI
|
